Insider Buying Activity Uncovered - 7 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Game-Changing Cancer Tech Nears FDA Completion]( [Explore Investment Opportunities in This Market Disruptor]( --------------------------------------------------------------- April 02, 2024 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time. [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- [Reddit, Inc.]( Ticker: [RDDT]( Recent Price: $45.97 Average Analyst Price Target: $54.00 (17.47%) Market Cap: $7.46B Role Transaction Description No. of Shares Amount Date COO Informative Buy Non Open Market Buy 9,274 $426,347 Yesterday Recent Analyst Action: Daniel Salmon, analyst at New Street, reiterates coverage on [Reddit, Inc. (RDDT)]( in the Communication Services sector with a Hold rating and a price target of $54 (6 days ago). Here are 3rd party ratings for [RDDT](: - TipRanks.com: Hold - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: n/a - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Author of Get Rich with Dividends Is Giving Away His Ultimate Dividend Package FOR FREE!]( Click Here to Get Marc Lichtenfeld's Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 9% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. [For Free.]( --------------------------------------------------------------- [Gain Therapeutics, Inc.]( Ticker: [GANX]( Recent Price: $3.83 Average Analyst Price Target: $9.00 (134.99%) Market Cap: $62.12M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 30,150 $115,500 Yesterday Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Gain Therapeutics, Inc. (GANX)]( in the Healthcare sector with a Buy rating and a price target of $9 (22 hours ago). Here are 3rd party ratings for [GANX](: - TipRanks.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 37% (93 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Alto Neuroscience, Inc.]( Ticker: [ANRO]( Recent Price: $14.56 Average Analyst Price Target: $32.33 (122.07%) Market Cap: $389.92M Role Transaction Description No. of Shares Amount Date CFO Informative Buy Non Open Market Buy 6,150 $100,628 Yesterday Recent Analyst Action: Ritu Baral, analyst at TD Cowen, reiterates coverage on [Alto Neuroscience, Inc. (ANRO)]( in the Healthcare sector with a Buy rating (1 week ago). Here are 3rd party ratings for [ANRO](: - TipRanks.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Top 31% (78 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [This Stock Could Go Up 66% or More.]( Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. [More here.]( --------------------------------------------------------------- [Gray Television, Inc.]( Ticker: [GTN]( Recent Price: $6.02 Average Analyst Price Target: $11.63 (93.11%) Market Cap: $604.62M Role Transaction Description No. of Shares Amount Date COB, Pres & CEO, Director Informative Buy Non Open Market Buy 13,400 $80,900 2 Days Ago Director Informative Buy Non Open Market Buy 13,400 $80,900 2 Days Ago Recent Analyst Action: James Goss, analyst at Barrington, reiterates coverage on [Gray Television, Inc. (GTN)]( in the Communication Services sector with a Hold rating (1 month ago). Here are 3rd party ratings for [GTN](: - TipRanks.com: Hold - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 15% (214 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Oncternal Therapeutics, Inc.]( Ticker: [ONCT]( Recent Price: $9.30 Average Analyst Price Target: $27.00 (190.32%) Market Cap: $27.52M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 6,290 $58,562 2 Days Ago Recent Analyst Action: Carl Byrnes, analyst at Northland Securities, reiterates coverage on [Oncternal Therapeutics, Inc. (ONCT)]( in the Healthcare sector with a Buy rating and a price target of $25 (3 weeks ago). Here are 3rd party ratings for [ONCT](: - TipRanks.com: Hold - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Top 37% (93 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [READ IMMEDIATELY: Huge banking overhaul underway]( The financial community has some big changes planned for your money. The Federal Reserve, US Treasury and White House are all involved... as are at least 41 American banks and credit unions. This overhaul could change how you cash your paycheck... access your social security income... even how you pay your taxes. That's why it's crucial you understand what's going on before your bank is affected. [Full story here.]( --------------------------------------------------------------- [HilleVax, Inc.]( Ticker: [HLVX]( Recent Price: $15.93 Average Analyst Price Target: $29.80 (87.07%) Market Cap: $791.73M Role Transaction Description No. of Shares Amount Date COO Informative Buy Non Open Market Buy 1,330 $21,225 2 Days Ago Recent Analyst Action: Stephen Willey, analyst at Stifel Nicolaus, reiterates coverage on [HilleVax, Inc. (HLVX)]( in the Healthcare sector with a Buy rating and a price target of $34 (1 week ago). Here are 3rd party ratings for [HLVX](: - TipRanks.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 31% (78 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Entrada Therapeutics, Inc.]( Ticker: [TRDA]( Recent Price: $13.76 Average Analyst Price Target: $21.00 (52.62%) Market Cap: $462.35M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 9,048 $122,808 7 Days Ago Director Informative Buy Non Open Market Buy 2,732 $34,988 8 Days Ago Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Entrada Therapeutics, Inc. (TRDA)]( in the Healthcare sector with a Buy rating and a price target of $20 (2 weeks ago). Here are 3rd party ratings for [TRDA](: - TipRanks.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Strong Sell, Top 31% (78 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Imminent FDA Decision Could End Obesity in America...]( [...and spark a 224,000% sales surge for one tiny micro-cap stock.]( The Wall Street Journal Reports: The "King Kong" of drugs is coming. Barron's Reports: "it's game changing." [Get the name of the stock here ]( --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor MarketSectorDaily.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be third-party advertisements where the advertiser is paying per click, per lead, or per sale and are not endorsed or warranted by our staff or company. SPMG, MarketSectorDaily.com and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged not to use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. SPMG, MarketSectorDaily.com nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from SPMG or MarketSectorDaily.com to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketSectorDaily.com MarketSectorDaily.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Mt. Mourne | North Carolina | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software